Combined administration with dihydroartemisinin-piperaquine resulted in significantly lower primaquine CL/F (P = 0.0229) and V/F (P = 0.0013) values than administration alone, leading to significantly higher Cmax (P = 0.0019) and AUC0–last (P = 0.0200) values. This also resulted in a shorter primaquine t1/2 (P = 0.0005) than with administration alone.
primaquine phosphate and dihydroartemisinin-piperaquine
primaquine phosphate
primaquine terminal elimination half-life; (t1/2)